Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaDr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series.
After completing her Master of Science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Disclosures
- Consultant/advisory role: Agendia; Amgen; AstraZeneca; Daiichi; Eisai; Gilead; Hologic; Lilly; Merck; Novartis; Pfizer; Puma; Sanofi; Sermonix; Stemline; Seagen
- Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- Methylphenidate vs Placebo for Treating Fatigue in Patients With Advanced Cancer
- Safety of Trastuzumab Deruxtecan With a Focus on Treatment-Related Interstitial Lung Disease and/or Pneumonitis
- Subgroup Analyses of the Outcomes of Sacituzumab Govitecan Therapy for Metastatic TNBC
- ASCO 2024: Abstract Recommendations From Dr. Reshma Mahtani for Breast Cancer
- Outcomes of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as Initial Therapy in Patients With HR+/HER2− Advanced Breast Cancer
- Outcomes of Tucatinib Combination Treatment After Trastuzumab Deruxtecan Therapy in Patients With ERBB2-Positive Metastatic Breast Cancer
- ESR1 Mutation Prevalence and Genomic Landscape Alterations in CDK4/6i-Treated HR+/HER2− Breast Cancer
- Longitudinal Profiling Identifies Co-Occurring BRCA1/2 Reversions and TP53BP1, RIF1, and PAXIP1 Mutations in PARP Inhibitor–Resistant Advanced Breast Cancer
- Toripalimab + Nab-Paclitaxel for Metastatic/Recurrent TNBC
- Pertuzumab Plus High-Dose Trastuzumab for HER2-Positive Breast Cancer With Brain Metastases